(redirected from Granix)


(tbo fil-gras-tim) ,


(trade name)


Therapeutic: colony stimulating factors
Pregnancy Category: C


To reduce the duration/severity of neutropenia in patients with non-myeloid malignancies who have received myelosuppressive antineoplastics associated with significant febrile neutropenia.


Binds to granulocyte-colony stimulating factor (G-CSF) receptors and stimulates proliferation of neutrophils.

Therapeutic effects

Increased neutrophil counts.


Absorption: 33% absorbed following subcutaneous administration.
Distribution: Recombinant G-CSF products are poorly secreted in breast milk.
Metabolism and Excretion: Unknown.
Half-life: 3.2–3.5 hr.

Time/action profile (increase in neutrophil count)

Subcutwithin 3 days3–5 days16–18 days


Contraindicated in: Hypersensitivity, including previous hypersensitivity to filgrastim or pegfilgrastim.
Use Cautiously in: Sickle cell disease; Obstetric: Use only if potential benefit justifies potential fetal risk; Lactation: Use cautiously; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects


  • acute respiratory distress syndrome (life-threatening)


  • splenic rupture (life-threatening)


  • rash
  • urticaria


  • sickle-cell crisis (life-threatening)
  • leukocytosis


  • bone pain (most frequent)


  • Allergic reactions including anaphylaxis and angioneurotic edema
  • potential for tumor growth stimulation


Drug-Drug interaction

Use cautiously with lithium ; may have additive effects on neutrophil release.


Subcutaneous (Adults and Children >18 yr) 5 mcg/kg per day; given no earlier than 24 hr following myelosuppressive chemotherapy; continue until expected neutrophil nadir is passed and neutrophil recovery has occurred.


Soluion for subcutaneous injection: 300 mcg/0.5 mL single-use prefilled syringe, 480 mcg/0.8 mL single-use prefilled syringe

Nursing implications

Nursing assessment

  • Assess for bone pain. Occurs commonly and may require treatment with acetaminophen or NSAIDs.
  • Monitor for signs of enlarged spleen or splenic rupture (upper abdominal pain, left shoulder pain, left upper quadrant pain).
  • Assess for acute respiratory distress syndrome (dyspnea with or without fever, fever, lung infiltrates, respiratory distress). May require discontinuation of tbo-filgrastim.
  • Monitor for signs and symptoms of allergic reactions (rash, urticaria, shortness of breath, wheezing, dizziness, swelling around mouth or eyes, fast heart rate, sweating). Administration of antihistamines, steroids, bronchodilators, and/or epinephrine may reduce severity of reactions. Permanently discontinue tbo-filgrastim if severe reactions occur.
  • Lab Test Considerations: Monitor CBC prior to chemotherapy and twice weekly until recovery.

Potential Nursing Diagnoses

Risk for infection (Indications)
Acute pain (Adverse Reactions)


  • Tbo-filgrastim should be administered by a health care professional.
  • Administer no earlier than 24 hr after chemotherapy.
    • Solution should be clear; do not administer solution that is discolored or contains particulate matter. Refrigerate; do not freeze. Do not shake. Syringe is for 1-time use only.
  • Subcutaneous: Inject into abdomen (except for 2 inch area around navel), front of middle thigh, upper outer area of buttocks, upper back portion of upper arm. Rotate site daily. Avoid area that is tender, red, bruised, hard, or has scars or stretch marks. Pinch skin gently and administer at 45° angle. Follow manufacturer's instructions for use of safety needle guard device.

Patient/Family Teaching

  • Explain purpose of injection to patient. Advise patient to read Patient Information sheet prior to administration.
  • Advise patient to notify health care professional immediately if signs and symptoms of rupture or enlargement of the spleen, acute respiratory distress syndrome, infection (fever, redness, swelling) or allergic reactions occur.
  • Discuss potential risks and benefits with patients with sickle cell disease prior to administration.
  • Advise patient to notify health care professional if bone pain becomes bothersome.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decreased incidence of infection in patients who receive bone marrow-depressing antineoplastics.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
M2 PHARMA-August 8, 2018-US FDA Approves Teva's Granix Injection for a New Vial Presentation
- The US Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for a new vial presentation and indication in pediatric patients 1 month and older, Israeli drugmaker Teva Pharmaceutical Industries Ltd.
FDA has approved GRANIX Injection for a new vial presentation and indication in pediatric patients 1 month and older.
Consent has one of the largest production capacity for concrete products in the UAE, exporting of masonry blocks, kerbstones, granix tiles and custom-made precast elements across the world.
The project was funded by Smart Communications and Granix Distributions Inc.
Not far behind, four companies are competing for second place: domestic Silcom SA with its La Abundancia cereals (14% projected share), Plucky SA, one of the companies from Grupo Bimbo SAB de CV (13%), Fortylex SA with its Kellogg's brand products (12%), and Promol Ltda (11%) with its Granix and Frutigran brands.
One of these previously approved products was tbofilgrastim (Granix, Teva), which was approved in August 2012.
Alimentos Granix, headquartered in Buenos Aires, Argentina, is one of the biggest cereal manufacturers in South America.
has announced two significant additions to its global oncology biologic portfolio with the recent launches of Lonquex (lipegfilgrastim) and Granix (tbo-filgrastim) Injection, and an update on the review status of balugrastim by the Food and Drug Administration.